secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001193125-24-227407
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves KarXT (Cobenfy) for schizophrenia; triggers $25M milestone for Royalty Pharma from PureTech deal
--------------------------------------------------------------------------------

- FDA approved KarXT (xanomeline-trospium) for adult schizophrenia; BMS to market as Cobenfy.
- Royalty Pharma's March 2023 PureTech deal: $100M upfront, up to $400M milestones, 3% royalty on sales up to $2B (then 1%).
- Approval triggers $25M milestone payment from Royalty Pharma to PureTech.
- Approval validates Royalty Pharma's investment and unlocks potential future royalty revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524227407/0001193125-24-227407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312524227407/d889954d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-227407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer